


PRODUCT INFORMATION



Alpidem

Item No. 34252

CAS Registry No.: 82626-01-5
Formal Name: 6-chloro-2-(4-chlorophenyl)-N,N-dipropyl-imidazo[1,2-a]pyridine-3-acetamide
MF: C₂₁H₂₃Cl₂N₃O
FW: 404.3
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Alpidem is supplied as a solid. A stock solution may be made by dissolving the alpidem in the solvent of choice, which should be purged with an inert gas. Alpidem is slightly soluble in chloroform and methanol.

Description

Alpidem is an anxiolytic agent.¹ It selectively binds to $\alpha_1\beta_2\gamma_2$ subunit-containing GABA_A receptors over $\alpha_5\beta_2\gamma_2$ subunit-containing GABA_A receptors in HEK293 cells (IC₅₀s = 0.017 and ≥10 μM, respectively, for the recombinant rat receptors).² Alpidem also binds to the GABA_A/benzodiazepine receptor complex and translocator protein 18 kDa (TSPO) with IC₅₀ values of 0.028 and 0.0079 μM, respectively.³ It reduces marble burying in mice, indicating anxiolytic activity, with a minimum effective dose (MED) of 10 mg/kg.⁴ Unlike the benzodiazepine alprazolam, alpidem does not induce sedation in mice when administered at doses up to 2 mg/kg.⁵ Formulations containing alpidem have previously been used in the treatment of generalized anxiety disorder.

References

1. Skolnick, P. Anxiolytic agents: On a quest for the holy grail. *Trends Pharmacol. Sci.* **33(11)**, 611-620 (2012).
2. Faure-Halley, C., Graham, D., Arbilla, S., et al. Expression and properties of recombinant $\alpha_1\beta_2\gamma_2$ and $\alpha_5\beta_2\gamma_2$ forms of the rat GABA_A receptor. *Eur. J. Pharmacol.* **246(3)**, 283-287 (1993).
3. Trapani, G., Franco, M.C., Ricciardi, L., et al. Synthesis and binding affinity of 2-phenylimidazo [1,2- α]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type. *J. Med. Chem.* **40(19)**, 3109-3118 (1997).
4. Zivkovic, B., Morel, E., Joly, D., et al. Pharmacological and behavioral profile of alpidem as an anxiolytic. *Pharmacopsychiatry* **23(Suppl. 3)**, 108-113 (1990).
5. Hascoët, M. and Bourin, M. Anticonflict effect of alpidem as compared with the benzodiazepine alprazolam in rats. *Pharmacol. Biochem. Behav.* **56(2)**, 317-324 (1997).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM